BlueAllele Gets Key Intellia Counterclaim Tossed in Patent Suit

BlueAllele Corp. convinced a federal judge to dismiss a claim that it wrongfully benefited from Intellia Therapeutics Inc.’s gene-editing inventions even as he allowed other counterclaims to proceed to discovery.

Judge John F. Murphy granted the part of BlueAllele’s Jan. 27 motion to dismiss centering on Intellia’s counterclaim for unjust enrichment because such disputes are governed by federal patent law, but he otherwise denied its requests, according to an order issued Feb. 21 in the US District Court for the District of Delaware.

Surviving counterclaims included Intellia’s requests to invalidate BlueAllele’s patents, correct inventorship, and declare Intellia as an owner ...